Posts tagged disease progression
Maxim downgrades Opexa Therapeutics to hold

Maxim Group downgraded Opexa Therapeutics (NASDAQ:OPXA) to “hold” from “buy” and removed its previous price target of $18 after the company failed a Phase 2b trial in secondary progressive multiple sclerosis (SPMS). The stock is changing hands at $1.02, down $2.37, in trading Friday afternoon.

Opexa’s T cell-based immunotherapy, Tcelna, did not meet the primary endpoint of brain atrophy and the secondary endpoint of reduced rate of disease progression also was not met

Read More
WB starts 4 chronic Hep B biotechs at outperform

William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier.

“Curing chronic hepatitis B infections is the next frontier after solving the hepatitis C problem, and the markets for both disease cures could be similar in size, reaching $200-billion each in cumulative global sales over a span of two decades,” writes analyst Katherine Xu.

Read More
ARIAD reports updated data in pivotal ALTA study

ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported updated clinical data for brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had experienced disease progression on crizotinib therapy.

The data show that, of patients on the 180 mg regimen (Arm B) with a median follow-up of 8.3 months, 54% achieved a confirmed objective response, the trial’s primary endpoint. In this arm, the median progression free survival exceeded one year (12.9 months) in this post-crizotinib setting.

Read More